SillaJen, Inc.

Sillajen Inc. is a biotechnology company focusing on the development of oncolytic immunotherapies. Its primary function is to harness the power of viruses to selectively kill cancer cells while stimulating a potent anti-tumor immune response. Sillajen’s technological innovation revolves around the modification and optimization of oncolytic viruses, primarily utilizing the Pexa-Vec platform, which is designed to treat a variety of cancers. The company has made significant strides in its research and clinical trials, impacting both the biotechnology and healthcare sectors. By targeting areas of high unmet medical need, Sillajen plays a vital role in advancing cancer treatment methodologies. Headquartered in South Korea, the firm is part of the growing landscape of companies working at the intersection of virotherapy and oncology, contributing to the global pursuit of breakthrough cancer therapies. Through strategic partnerships and collaborations, Sillajen is positioned to influence future therapeutic approaches within the biotech industry.